Melissa Y. Yeung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Melissa Y. Yeung has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Mohamed H. Sayegh
Department of Medicine, Renal Division, Brigham and Women's Hospital, Boston, MA, USA
2 shared publications- William J. Lane
Department of Pathology Brigham and Women's Hospital Boston Massachusetts USA
2 shared publications A. Waisman
Institute for Molecular Medicine, Johannes Gutenberg University Mainz, Mainz, Germany
1 shared publication- Abigail Joseph
Harvard Medical School, Boston, MA, USA
1 shared publication - Amr Mansouri
Transplantation Research Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
1 shared publication - Anu Paul
Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
1 shared publication
Latest Publications
- 10 May 2026
- Published by Elsevier in Human Immunology
- Vol. 87 (7) , 111758
The “next” standard for ABO genotyping
- 10 May 2026
- Published by Elsevier in Human Immunology
- Vol. 87 (7) , 111758
The “next” standard for ABO genotyping
- Open Access
- 13 March 2024
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 23 (5) , 100747
Galectin-4 Antimicrobial Activity Primarily Occurs Through its C-Terminal Domain
- 13 March 2024
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 23 (5) , 100747
Open AccessGalectin-4 Antimicrobial Activity Primarily Occurs Through its C-Terminal Domain
- Open Access
- 29 May 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (9) , 1388-1400
Impact of allele-specific anti–human leukocyte antigen class I antibodies on organ allocation
- 29 May 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (9) , 1388-1400
Open AccessImpact of allele-specific anti–human leukocyte antigen class I antibodies on organ allocation
- Open Access
- 22 December 2022
- Published by Elsevier in Seminars in Nephrology
- Vol. 42 (4) , 151274
Kidney Organ Allocation System: How to Be Fair
- 22 December 2022
- Published by Elsevier in Seminars in Nephrology
- Vol. 42 (4) , 151274
Open AccessKidney Organ Allocation System: How to Be Fair
- 23 May 2022
- Published by Elsevier in Seminars in Nephrology
- Vol. 42 (1) , 44-62
Histocompatibility Assessment in Precision Medicine for Transplantation: Towards a Better Match
- 23 May 2022
- Published by Elsevier in Seminars in Nephrology
- Vol. 42 (1) , 44-62
Histocompatibility Assessment in Precision Medicine for Transplantation: Towards a Better Match
- Open Access
- 1 June 2020
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 42 (2) , 136-137
Pre-formed DSA and kidney allograft outcomes
DSA detected by the complement-dependent cytotoxicity (CDC) crossmatch are considered an absolute contraindication for transplantation because of their propensity to cause hyperacute rejection3, whereas DSA detected by other assays represent varying degrees of immunological risk4. Transplant centers currently use results of the single antigen bead assay at a pre-defined, low-threshold cutoff to exclude candidates from being eligible for an organ to which they have a DSA. This practice errs on the side of caution by assuming that any low-level antibody affects graft survival and that avoidance of these antigens will result in a better “matched” kidney for the recipient and improve the likelihood of long-term graft survival. However, this approach also restricts a recipient’s access to organs and may lead to longer wait times, particularly for candidates who are highly sensitized. Sensitized candidates have limited access to transplantation in proportion to how broadly their anti-HLA antibodies react with those of the donor. For these patients, use of an organ against which they have preformed DSA may be inevitable. It is estimated that 25% of patients with cPRA will not receive an offer under the current deceased donor organ allocation system in the United States5. For these patients, transplantation is possible only if low-level antibody is crossed, or desensitization strategies pursued. It remains unclear which patients would benefit from earlier transplantation with an HLA-incompatible donor versus remaining on dialysis in hopes of finding a more compatible match.
- 1 June 2020
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 42 (2) , 136-137
Open AccessPre-formed DSA and kidney allograft outcomes
DSA detected by the complement-dependent cytotoxicity (CDC) crossmatch are considered an absolute contraindication for transplantation because of their propensity to cause hyperacute rejection3, whereas DSA detected by other assays represent varying degrees of immunological risk4. Transplant centers currently use results of the single antigen bead assay at a pre-defined, low-threshold cutoff to exclude candidates from being eligible for an organ to which they have a DSA. This practice errs on the side of caution by assuming that any low-level antibody affects graft survival and that avoidance of these antigens will result in a better “matched” kidney for the recipient and improve the likelihood of long-term graft survival. However, this approach also restricts a recipient’s access to organs and may lead to longer wait times, particularly for candidates who are highly sensitized. Sensitized candidates have limited access to transplantation in proportion to how broadly their anti-HLA antibodies react with those of the donor. For these patients, use of an organ against which they have preformed DSA may be inevitable. It is estimated that 25% of patients with cPRA will not receive an offer under the current deceased donor organ allocation system in the United States5. For these patients, transplantation is possible only if low-level antibody is crossed, or desensitization strategies pursued. It remains unclear which patients would benefit from earlier transplantation with an HLA-incompatible donor versus remaining on dialysis in hopes of finding a more compatible match.
- Open Access
- 28 February 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (11) , 6042-6046
Regulatory CD8 T cells that recognize Qa-1 expressed by CD4 T-helper cells inhibit rejection of heart allografts
Significance: There is increasing evidence that CD8 + regulatory T cells (CD8 Treg) can modulate the immune response in the context of autoimmune disease, infection, and cancer. Here we asked whether this regulatory mechanism might control the host response to transplanted heart allografts. We report that CD8 Treg that recognize Qa-1, the murine homolog of HLA-E, strongly inhibits host production of antibodies specific for the donor organ. Since the production of antidonor antibodies is currently a major barrier to successful transplantation, identification of this Qa-1/HLA-E-dependent pathway may pave the way to approaches to this pressing clinical problem.
- 28 February 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (11) , 6042-6046
Open AccessRegulatory CD8 T cells that recognize Qa-1 expressed by CD4 T-helper cells inhibit rejection of heart allografts
Significance: There is increasing evidence that CD8 + regulatory T cells (CD8 Treg) can modulate the immune response in the context of autoimmune disease, infection, and cancer. Here we asked whether this regulatory mechanism might control the host response to transplanted heart allografts. We report that CD8 Treg that recognize Qa-1, the murine homolog of HLA-E, strongly inhibits host production of antibodies specific for the donor organ. Since the production of antidonor antibodies is currently a major barrier to successful transplantation, identification of this Qa-1/HLA-E-dependent pathway may pave the way to approaches to this pressing clinical problem.
- 23 November 2019
- Published by Springer Nature
- Vol. 1189, 267-312
Costimulation Blockade in Transplantation
T cells play a pivotal role in orchestrating immune responses directed against a foreign (allogeneic) graft. For T cells to become fully activated, the T-cell receptor (TCR) must interact with the major histocompatibility complex (MHC) plus peptide complex on antigen-presenting cells (APCs), followed by a second “positive” costimulatory signal. In the absence of this second signal, T cells become anergic or undergo deletion. By blocking positive costimulatory signaling, T-cell allo-responses can be aborted, thus preventing graft rejection and promoting long-term allograft survival and possibly tolerance (Alegre ML, Najafian N, Curr Mol Med 6:843–857, 2006; Li XC, Rothstein DM, Sayegh MH, Immunol Rev 229:271–293, 2009). In addition, costimulatory molecules can provide negative “coinhibitory” signals that inhibit T-cell activation and terminate immune responses; strategies to promote these pathways can also lead to graft tolerance (Boenisch O, Sayegh MH, Najafian N, Curr Opin Organ Transplant 13:373–378, 2008). However, T-cell costimulation involves an incredibly complex array of interactions that may act simultaneously or at different times in the immune response and whose relative importance varies depending on the different T-cell subsets and activation status. In transplantation, the presence of foreign alloantigen incites not only destructive T effector cells but also protective regulatory T cells, the balance of which ultimately determines the fate of the allograft (Lechler RI, Garden OA, Turka LA, Nat Rev Immunol 3:147–158, 2003). Since the processes of alloantigen-specific rejection and regulation both require activation of T cells, costimulatory interactions may have opposing or synergistic roles depending on the cell being targeted. Such complexities present both challenges and opportunities in targeting T-cell costimulatory pathways for therapeutic purposes. In this chapter, we summarize our current knowledge of the various costimulatory pathways in transplantation and review the current state and challenges of harnessing these pathways to promote graft tolerance (summarized in Table 10.1).
- 23 November 2019
- Published by Springer Nature
- Vol. 1189, 267-312
Costimulation Blockade in Transplantation
T cells play a pivotal role in orchestrating immune responses directed against a foreign (allogeneic) graft. For T cells to become fully activated, the T-cell receptor (TCR) must interact with the major histocompatibility complex (MHC) plus peptide complex on antigen-presenting cells (APCs), followed by a second “positive” costimulatory signal. In the absence of this second signal, T cells become anergic or undergo deletion. By blocking positive costimulatory signaling, T-cell allo-responses can be aborted, thus preventing graft rejection and promoting long-term allograft survival and possibly tolerance (Alegre ML, Najafian N, Curr Mol Med 6:843–857, 2006; Li XC, Rothstein DM, Sayegh MH, Immunol Rev 229:271–293, 2009). In addition, costimulatory molecules can provide negative “coinhibitory” signals that inhibit T-cell activation and terminate immune responses; strategies to promote these pathways can also lead to graft tolerance (Boenisch O, Sayegh MH, Najafian N, Curr Opin Organ Transplant 13:373–378, 2008). However, T-cell costimulation involves an incredibly complex array of interactions that may act simultaneously or at different times in the immune response and whose relative importance varies depending on the different T-cell subsets and activation status. In transplantation, the presence of foreign alloantigen incites not only destructive T effector cells but also protective regulatory T cells, the balance of which ultimately determines the fate of the allograft (Lechler RI, Garden OA, Turka LA, Nat Rev Immunol 3:147–158, 2003). Since the processes of alloantigen-specific rejection and regulation both require activation of T cells, costimulatory interactions may have opposing or synergistic roles depending on the cell being targeted. Such complexities present both challenges and opportunities in targeting T-cell costimulatory pathways for therapeutic purposes. In this chapter, we summarize our current knowledge of the various costimulatory pathways in transplantation and review the current state and challenges of harnessing these pathways to promote graft tolerance (summarized in Table 10.1).
- 30 January 2017
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 17 (3) , 339-352
Use of polyclonal/monoclonal antibody therapies in transplantation
Introduction: For over thirty years, antibody (mAb)-based therapies have been a standard component of transplant immunosuppression, and yet much remains to be learned in order for us to truly harness their therapeutic capabilities. Current mAbs used in transplant directly target and destroy graft-destructive immune cells, interrupt cytokine and costimulation-dependent T and B cell activation, and prevent down-stream complement activation. Areas covered: This review summarizes our current approaches to using antibody-based therapies to prevent and treat allograft rejection. It also provides examples of promising novel mAb therapies, and discusses the potential for future mAb development in transplantation. Expert opinion: The broad capability of antibodies, in parallel with our growing ability to synthetically modulate them, offers exciting opportunities to develop better biologic therapeutics. In order to do so, we must further our understanding about the basic biology underlying allograft rejection, and gain better appreciation of how characteristics of therapeutic antibodies affect their efficacy.
- 30 January 2017
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 17 (3) , 339-352
Use of polyclonal/monoclonal antibody therapies in transplantation
Introduction: For over thirty years, antibody (mAb)-based therapies have been a standard component of transplant immunosuppression, and yet much remains to be learned in order for us to truly harness their therapeutic capabilities. Current mAbs used in transplant directly target and destroy graft-destructive immune cells, interrupt cytokine and costimulation-dependent T and B cell activation, and prevent down-stream complement activation. Areas covered: This review summarizes our current approaches to using antibody-based therapies to prevent and treat allograft rejection. It also provides examples of promising novel mAb therapies, and discusses the potential for future mAb development in transplantation. Expert opinion: The broad capability of antibodies, in parallel with our growing ability to synthetically modulate them, offers exciting opportunities to develop better biologic therapeutics. In order to do so, we must further our understanding about the basic biology underlying allograft rejection, and gain better appreciation of how characteristics of therapeutic antibodies affect their efficacy.
- Open Access
- 6 June 2016
- Published by Elsevier in American Journal of Transplantation
- Vol. 16 (11) , 3139-3149
Inflammation Causes Resistance to Anti-CD20–Mediated B Cell Depletion
- 6 June 2016
- Published by Elsevier in American Journal of Transplantation
- Vol. 16 (11) , 3139-3149
Open AccessInflammation Causes Resistance to Anti-CD20–Mediated B Cell Depletion